

Claims

1. Method for the treatment of schizophrenia with an antipsychotic agent administered to a patient with overweight wherein that the antipsychotic agent is
5 asenapine.
2. Method for the treatment with asenapine of schizophrenia in a patient that was having weight gain due to another antipsychotic agent.
- 10 3. Method for the treatment with asenapine of schizophrenia in a patient that needs to be protected against weight increase due to the presence of risk factors for a disease for which overweight is also a risk factor or due to the presence of other weight increasing factors.
- 15 4. The method according to claim 1 wherein the overweight is defined to be a BMI of ≥ 25 .
- 20 5. The method according to claim 4 wherein the overweight is defined to be a BMI of ≥ 27.8 for men and ≥ 27.3 for women.
6. The method according to any one of claims 1 – 5 wherein asenapine is administered to the patient by the sublingual route.
- 25 7. Use of an antipsychotic agent in the manufacture of a medicament for the treatment of schizophrenia in a patient with overweight wherein the antipsychotic agent is asenapine.
8. Use of asenapine in the manufacture of a medicament for the treatment of schizophrenia administered to a patient wherein the patient was having weight gain
30 due to another antipsychotic agent.
9. Use of asenapine in the manufacture of a medicament for the treatment of schizophrenia administered to a patient wherein the patient needs to be protected against weight increase due to the presence of risk factors for a disease for which
35 overweight is also a risk factor or due to the presence of other weight increasing factors.
10. The use of claim 7 wherein the overweight is defined to be a BMI of ≥ 25 .

11. The use of claim 9 wherein the overweight is defined to be a BMI of ≥ 27.8 for men and ≥ 27.3 for women.

5 12. The use of claims 7-11 wherein the medicament is to be administered to the patient by the sublingual route.